Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 373 results for "mirati"

Equities Research Analysts Upgrades for May, 6th (ABCO, ACRX, ARCX, CAE, CNNX, CRME, DISCA, IMMU, MAC, MDVN)
American Banking News - Earnings

Short Interest in Mirati Therapeutics, Inc. (MRTX) Grows By 28.5%

Mirati Therapeutics, Inc. (NASDAQ:MRTX) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 1,701,838 shares, an increase of 28.5% from the May 31st total of 1,324,633 ... American Banking News, 9 hours ago
[x]  

10 images for mirati

ADVFN India, 5 days ago
FOXBusiness.com, 3 weeks ago
FOXBusiness.com, 3 weeks ago
Schaeffers Research, 3 weeks ago
Nasdaq, 3 weeks ago
Motley Fool, 3 weeks ago
BioSpace, 3 weeks ago
Yahoo! Singapore, 3 weeks ago
Yahoo! Singapore, 3 weeks ago
Oregon Public Broadcasting, 1 month ago

Stocks Hitting 52-Week Lows

Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares touched a new 52-week low of $6.54. Mirati Therapeutics shares have dropped 78.59 percent over the past 52 weeks, while the S&P 500 index has declined 1.84 percent in the same period. Adamis ...
 Benzinga.com1 week ago Mirati Therapeutics Shares Plunge 40%; Jefferies Downgrades To Hold  Benzinga.com3 weeks ago

Mirati Therapeutics operations chief bids adieu

Mirati Therapeutics (NASDAQ: MRTX ) EVP and Chief Operations Officer Mark Gergen resigns to pursue other interests. No word is given on the search for a successor. Board Chairman Rodney Lappe, Ph.D., will assume the role of Executive Chairman, ...
 Seeking Alpha5 days ago

Insider Buys of More Than $aaa,aaa: Mirati Therapeutics

- By alicet236 Mirati Therapeutics Inc. (MRTX) President and CEO Charles M. Baum bought 20,000 shares on June 14 at an average price of $7.05 per share. The total transaction amount was $141,000. Mirati Therapeutics has a market cap of $140.370 ...
 Yahoo! Finance1 week ago Insider Buys of More Than $……,………: Mirati Therapeutics  Guru Focus1 week ago

Mirati Therapeutics, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 8, 2016)

By a News Reporter-Staff News Editor at -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Mirati Therapeutics, Inc. (Form 4) was posted on June 8, 2016 ...
 Equities.com4 days ago SC 13D/A - Mirati Therapeutics, Inc. (0001576263) (Subject)  SEC Filings2 weeks ago Boxer Capital Just increased Mirati Therapeutics Inc's Stake  Octafinance2 weeks ago MIRATI THERAPEUTICS, INC. FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits  Equities.com3 weeks ago
[x]  

Mirati Takes Home The Share Price Wooden Spoon

The tradition of wild biotech stock price movements on Asco Monday when investors get their first opportunity to react to clinical data emerging over the weekend was rather muted this year, reflecting the relative absence of high-impact late-stage ...
 Seeking Alpha3 weeks ago
Motley Fool

Why Sturm Ruger, Mirati Therapeutics, and Barracuda Networks Slumped Today

Monday brought a solid reversal to the downward movement stock market investors suffered late last week. Major market benchmarks rose between 0.5% and 0.75% as market participants chose to see the positives in comments from U.S. central bank chief ...
 Motley Fool3 weeks ago
Motley Fool

Why Mirati Therapeutics, Inc.'s Shares Are Being Obliterated Today

What: Investors in Mirati Therapeutics ( NASDAQ:MRTX ) are having a rough start to the week. The clinical-stage biotech's stock is down more than 40% as of 11:30 a.m. EDT after management shared a few clinical updates that caused some investors to ...
 Motley Fool3 weeks ago

Side effects excessive in early-stage study of Mirati's lead product candidate, new formulation being implemented in Phase 2; shares off 40%

Thinly traded micro cap Mirati Therapeutics ( MRTX -40.1%) plummets in early trading on a 6x surge in volume in response to its update on its clinical trials. The company reported results from a Phase 1b study evaluating lead product glesatinib , a ...
 Seeking Alpha3 weeks ago

Mirati Therapeutics misses by $0.14

News Editor Mirati Therapeutics (NASDAQ:MRTX): Q1 EPS of -$1.13 misses by $0.14. Comments (0) Be the first to comment All (0) Author's Picks () Load All Comments DJIA (DIA) S&P 500 (SPY) ETF Hub ETF Screener: Search and filter by ...
 Seeking Alpha1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less